KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vertex Pharmaceuticals (VRTX) Operating Income (2016 - 2025)

Vertex Pharmaceuticals (VRTX) has 17 years of Operating Income data on record, last reported at $1.2 billion in Q4 2025.

  • For Q4 2025, Operating Income rose 17.53% year-over-year to $1.2 billion; the TTM value through Dec 2025 reached $4.2 billion, up 1891.88%, while the annual FY2025 figure was $4.2 billion, 1891.88% up from the prior year.
  • Operating Income reached $1.2 billion in Q4 2025 per VRTX's latest filing, up from $1.2 billion in the prior quarter.
  • Across five years, Operating Income topped out at $1.2 billion in Q4 2025 and bottomed at -$3.5 billion in Q2 2024.
  • Average Operating Income over 5 years is $743.1 million, with a median of $1.0 billion recorded in 2022.
  • Peak YoY movement for Operating Income: soared 3014.31% in 2022, then tumbled 442.43% in 2024.
  • A 5-year view of Operating Income shows it stood at $877.7 million in 2021, then rose by 17.75% to $1.0 billion in 2022, then decreased by 4.35% to $988.5 million in 2023, then rose by 3.79% to $1.0 billion in 2024, then grew by 17.53% to $1.2 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Operating Income were $1.2 billion in Q4 2025, $1.2 billion in Q3 2025, and $1.2 billion in Q2 2025.